LENZ Therapeutics (LENZ) Assets Average (2021 - 2026)

LENZ Therapeutics (LENZ) has 6 years of Assets Average data on file, last reported at $289.2 million in Q1 2026.

• On a quarterly basis, Assets Average rose 38.86% year-over-year to $289.2 million in Q1 2026; TTM through Mar 2026 was $289.2 million, a 38.86% increase from a year earlier, with the FY2025 full-year figure at $260.6 million, up 82.43% from the prior year.
• Assets Average for Q1 2026 stood at $289.2 million, up from $258.3 million in the prior quarter.
• Over the last five years, Assets Average for LENZ reached as high as $390.3 million in Q1 2022 and fell as low as $143.8 million in Q1 2024.
• Historically, Assets Average has averaged $262.0 million across 5 years, with a median of $258.3 million in 2025.
• Across the five-year window, Assets Average tumbled 54.47% in 2024 and jumped 44.79% in 2025, its largest moves.
• Year by year, Assets Average stood at $328.4 million in 2022, then tumbled by 48.75% to $168.3 million in 2023, then surged by 30.51% to $219.7 million in 2024, then climbed by 17.59% to $258.3 million in 2025, then increased by 11.97% to $289.2 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $289.2 million in Q1 2026, $258.3 million in Q4 2025, and $214.0 million in Q3 2025.